GluK2是耐药性颞叶癫痫基因治疗的靶点
研究在啮齿类TLE模型和耐药性TLE患者海马切片中,用AAV9递送抗grik2 miRNA下调GluK2表达,结果小鼠癫痫活动明显减少,患者切片中GluK2蛋白水平降低且发作间期样癫痫放电显著减少,为靶向GluK2的基因治疗提供了概念验证。
要点
- 非选择性KAR拮抗剂可明显减弱耐药性TLE患者海马切片中的发作间期样癫痫放电。
- AAV9-抗grik2 miRNA直接递送至TLE小鼠海马可明显减少癫痫活动。
- 转导TLE患者海马切片可降低GluK2蛋白水平并显著减少发作间期样癫痫放电。
核心结论
- 敲低异常GluK2表达的基因沉默策略在小鼠TLE模型中抑制慢性癫痫发作,在TLE患者来源的培养切片中抑制发作间期样癫痫放电。
- 这些结果为靶向GluK2 KARs的基因治疗用于耐药性TLE患者提供了概念验证。
研究设计与样本
- 研究结合分子生物学与电生理学,在啮齿类TLE模型和手术切除的耐药性TLE患者海马切片中进行。
- 构建表达抗grik2 miRNA的腺相关病毒血清型9(AAV9)载体以特异性下调GluK2表达。
主要发现
- 非选择性KAR拮抗剂明显减弱TLE患者来源海马切片中的发作间期样癫痫放电。
- AAV9-抗grik2 miRNA直接递送至TLE小鼠海马导致癫痫活动明显减少。
- 转导TLE患者海马切片降低GluK2蛋白水平,并显著减少发作间期样癫痫放电。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Temporal lobe epilepsy (TLE) is characterized by recurrent seizures generated in the limbic system, particularly in the hippocampus. In TLE, recurrent mossy fiber sprouting from dentate gyrus granule cells (DGCs) crea an aberrant epileptogenic network between DGCs which operates via ectopically expressed GluK2/GluK5-containing kainate receptors (KARs). TLE patients are often resistant to anti-seizure medications and suffer significant comorbidities; hence, there is an urgent need for novel therapies. Previously, we have shown that GluK2 knockout mice are protected from seizures. This study aims at providing evidence that downregulating KARs in the hippocampus using gene therapy reduces chronic epileptic discharges in TLE. METHODS: We combined molecular biology and electrophysiology in rodent models of TLE and in hippocampal slices surgically resected from patients with drug-resistant TLE. RESULTS: Here, we confirmed the translational potential of KAR suppression using a non-selective KAR antagonist that markedly attenuated interictal-like epileptiform discharges (IEDs) in TLE patient-derived hippocampal slices. An adeno-associated virus (AAV) serotype-9 vector expressing anti-grik2 miRNA was engineered to specifically downregulate GluK2 expression. Direct delivery of AAV9-anti grik2 miRNA into the hippocampus of TLE mice led to a marked reduction in seizure activity. Transduction of TLE patient hippocampal slices reduced levels of GluK2 protein and, most importantly, significantly reduced IEDs. INTERPRETATION: Our gene silencing strategy to knock down aberrant GluK2 expression demonstrates inhibition of chronic seizure in a mouse TLE model and IEDs in cultured slices derived from TLE patients. These results provide proof-of-concept for a gene therapy approach targeting GluK2 KARs for drug-resistant TLE patients. ANN NEUROL 2023;94:745-761.
引用
- Boileau C, Deforges S, Peret A, et al. GluK2 Is a Target for Gene Therapy in Drug-Resistant Temporal Lobe Epilepsy. Ann Neurol. 2023. PMID: 37341588. doi:10.1002/ana.26723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。